Dr. Peter F. Crossno, MD
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
5121 Cottonwood St, Intermountain Medical Center Ricu
Murray, UT 84107
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 108
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
UT license 5413984-1205 -
Internal Medicine Physician
UT license 5413984-1205 -
Pulmonary Disease Physician
UT license 5413984-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Medical Center Murray, UT
- St. George Regional Hospital St George, UT
- Intermountain Health Riverton Hospital Riverton, UT
- Intermountain Health St Vincent Regional Hospital Billings, MT
- Intermountain Health Alta View Hospital Sandy, UT
Medical groups
- Ihc Health Services Inc (3,960 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 108
- Services billed
- 205
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 47 | 36 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 23 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 15 |
| Established patient office or other outpatient visit, 20-29 minutes | 17 | 16 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 64 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Murray, UT | 47 |
| Prednisone Other prescribers in Murray, UT | 32 |
| Oxycodone Hcl Other prescribers in Murray, UT | 22 |
| Fluticasone Propionate Other prescribers in Murray, UT | 22 |
| Methotrexate (methotrexate sodium) Other prescribers in Murray, UT | 20 |
| Tyvaso Dpi (treprostinil) | 17 |
| Potassium Chloride Other prescribers in Murray, UT | 16 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Murray, UT | 15 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Murray, UT | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 16 payments worth $8,832 in total to this clinician.
| United Therapeutics Corporation | $8,757 |
|---|---|
| Verona Pharma, Inc. | $49.66 |
| Baxter Healthcare | $25.71 |
| Consulting Fee | $6,950 |
|---|---|
| Travel and Lodging | $1,120 |
| Food and Beverage | $762 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation Jul 25, 2025 | Consulting Fee TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun | $6,950 |
| United Therapeutics Corporation Jul 24, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Detroit, MI · in-kind | $724 |
| United Therapeutics Corporation Jul 24, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Detroit, MI · in-kind | $298 |
| United Therapeutics Corporation Jul 25, 2025 | Travel and Lodging TYVASO · Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lun · travel to Detroit, MI | $98.07 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $286,823 in research payments for these studies, mostly to the institutions running them.
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics Corporation · Completed · NCT05776225
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.